> Detailanzeige

Müller, Jana; Weiler, Markus; Schneeweiss, Andreas; Haag, Georg Martin; Steindorf, Karen; Wick, Wolfgang; Wiskemann, Joachim

Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial
  • Beteiligte: Müller, Jana; Weiler, Markus; Schneeweiss, Andreas; Haag, Georg Martin; Steindorf, Karen; Wick, Wolfgang; Wiskemann, Joachim
  • Erschienen: Springer Science and Business Media LLC, 2021
  • Erschienen in: British Journal of Cancer
  • Sprache: Englisch
  • DOI: 10.1038/s41416-021-01471-1
  • ISSN: 0007-0920; 1532-1827
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a common, unpleasant and usually long-lasting side effect of neurotoxic chemotherapeutic agents. This study aimed to investigate the preventive potential of sensorimotor- (SMT) and resistance training (RT) on CIPN.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Patients (<jats:italic>N</jats:italic> = 170) were randomised to SMT, RT or usual care (UC). Both exercise groups trained 3×/week for a total of 105 min/week during neurotoxic chemotherapy (mean length: 20 weeks). Before and 3 weeks after neurotoxic chemotherapy, CIPN signs/symptoms were assessed via Total Neuropathy Score (TNSr; primary endpoint) and EORTC QLQ-CIPN15 questionnaire. In addition, balance (centre of pressure), muscle strength (isokinetic), quality of life (QoL, EORTC QLQ-C30) and relative chemotherapy dose intensity (RDI) were investigated. The follow-up period covered 6 months after the end of chemotherapy.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Intention-to-treat analyses (<jats:italic>N</jats:italic> = 159) revealed no differences regarding CIPN signs/symptoms. Exploratory per-protocol analyses (minimum training attendance rate 67%; <jats:italic>N</jats:italic> = 89) indicated that subjectively perceived sensory symptoms in the feet increased less during chemotherapy in the adherent exercisers (pooled group: SMT+RT) than in the UC group (−8.3 points (−16.1 to −0.4); <jats:italic>P</jats:italic> = 0.039, ES = 1.27). Furthermore, adherent exercisers received a higher RDI (96.6 ± 4.8 vs. 92.2 ± 9.4; <jats:italic>P</jats:italic> = 0.045), showed a better course of muscular strength (+20.8 Nm (11.2–30.4); <jats:italic>P</jats:italic> &lt; 0.001, ES = 0.57) and QoL (+12.9 points (3.9–21.8); <jats:italic>P</jats:italic> = 0.005, ES = 0.64). During follow-up, CIPN signs/symptoms persisted in all groups.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>This study demonstrates that SMT and/or RT alleviate subjectively perceived sensory CIPN symptoms in the feet and other clinically relevant cancer therapy-related outcomes, if an appropriate training stimulus is achieved.</jats:p> </jats:sec><jats:sec> <jats:title>Clinical trial registration</jats:title> <jats:p>NCT02871284.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang